,chromosome,createDate,entrezId,geneDescriptions,geneSymbol,id,mapLocation,synonyms,terms,updateDate
0,9,05/26/2013,25,"[{'description': 'ABL1, ABL proto-oncogene 1, non-receptor tyrosine kinase, is a non-receptor tyrosine kinase, which plays a role in regulation of cell growth through ERK5, Rac/JNK, and Stat1/3 pathways (PMID: 10373409). Fusion proteins of BCR-ABL1 result in constitutive kinase activity and have been reported in various cancers (PMID: 18851712).', 'references': [{'id': 9801, 'pubMedId': 10373409, 'title': 'Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10373409'}, {'id': 120, 'pubMedId': 18851712, 'title': 'Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18851712'}]}]",ABL1,25,9q34.12,"['ABL', 'bcr/abl', 'c-ABL', 'c-ABL1', 'CHDSKM', 'JTK7', 'p150', 'v-abl']","['ABL1', 'ABL', 'bcr/abl', 'c-ABL', 'c-ABL1', 'CHDSKM', 'JTK7', 'p150', 'v-abl']",08/28/2017
0,14,05/26/2013,207,"[{'description': 'AKT1 is a serine-threonine protein kinase, which regulates cell proliferation and survival through PI3K signaling (PMID: 23297823). AKT1 is frequently hyperactivated in cancer (PMID: 23134728).', 'references': [{'id': 9003, 'pubMedId': 23297823, 'title': 'Diverse mechanisms of AKT pathway activation in human malignancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23297823'}, {'id': 103, 'pubMedId': 23134728, 'title': 'Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23134728'}]}]",AKT1,207,14q32.33,"['AKT', 'CWS6', 'PKB', 'PKB-ALPHA', 'PRKBA', 'RAC', 'RAC-ALPHA']","['AKT1', 'AKT', 'CWS6', 'PKB', 'PKB-ALPHA', 'PRKBA', 'RAC', 'RAC-ALPHA']",07/24/2017
0,2,05/29/2013,238,"[{'description': 'ALK, anaplastic lymphoma receptor tyrosine kinase, is a receptor in the insulin receptor superfamily and is a key regulator of neuronal development (PMID: 21502284). ALK activating mutations and fusions have been commonly identified in various cancers (PMID: 22649787).', 'references': [{'id': 105, 'pubMedId': 21502284, 'title': 'Anaplastic lymphoma kinase in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21502284'}, {'id': 107, 'pubMedId': 22649787, 'title': 'ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649787'}]}]",ALK,238,2p23.2-p23.1,"['CD246', 'NBLST3']","['ALK', 'CD246', 'NBLST3']",07/24/2017
0,5,05/25/2013,324,"[{'description': 'APC, adenomatous polyposis coli, is a multi-domain protein regulating numerous cellular functions through interaction with beta-catenin and subsequent inhibition of Wnt signalling (PMID: 21502284). APC germline mutations are associated with familial adenomatous polyposis and somatic mutations with colon, endometrial, NSCLC, and breast cancers (PMID: 27283171).', 'references': [{'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}, {'id': 105, 'pubMedId': 21502284, 'title': 'Anaplastic lymphoma kinase in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21502284'}]}]",APC,324,5q22.2,"['BTPS2', 'DP2', 'DP2.5', 'DP3', 'GS', 'PPP1R46']","['APC', 'BTPS2', 'DP2', 'DP2.5', 'DP3', 'GS', 'PPP1R46']",07/24/2017
0,20,05/22/2013,171023,"[{'description': 'ASXL1, additional sex combs like 1, is involved in epigenetic regulation of gene expression and forms complexes with several proteins to regulate transcription (PMID: 23736028). Mutations in ASXL1 have been associated with a number of different cancers including cervical, colon, CLL, and squamous cell carcinoma (PMID: 23736028).', 'references': [{'id': 207, 'pubMedId': 23736028, 'title': 'Functional and cancer genomics of ASXL family members.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23736028'}]}]",ASXL1,171023,20q11.21,"['BOPS', 'MDS']","['ASXL1', 'BOPS', 'MDS']",07/24/2017
0,11,05/26/2013,472,"[{'description': 'ATM, ataxia-telangiectasia mutated protein kinase, is a member of the serine-threonine kinase family and coordinates cellular responses to DNA damage through activation of distinct DNA repair and signaling pathways (PMID: 22079189). ATM somatic mutations are associated with endometrial, colon, pancreatic, and breast cancers (PMID: 27283171).', 'references': [{'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}, {'id': 106, 'pubMedId': 22079189, 'title': 'The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22079189'}]}]",ATM,472,11q22.3,"['AT1', 'ATA', 'ATC', 'ATD', 'ATDC', 'ATE', 'TEL1', 'TELO1']","['ATM', 'AT1', 'ATA', 'ATC', 'ATD', 'ATDC', 'ATE', 'TEL1', 'TELO1']",07/24/2017
0,X,05/22/2013,546,"[{'description': 'ATRX, transcriptional regulator ATRX, is in the SWI/SNF family of chromatin remodeling proteins and plays a role in DNA repair and telomere length. ATRX loss has been identified in a high percentage of tumor types including glioma (PMID: 23249563; PMID: 26936505).', 'references': [{'id': 112, 'pubMedId': 23249563, 'title': 'ATRX: the case of a peculiar chromatin remodeler.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23249563'}, {'id': 5444, 'pubMedId': 26936505, 'title': 'ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936505'}]}]",ATRX,546,Xq21.1,"['JMS', 'MRX52', 'RAD54', 'RAD54L', 'XH2', 'XNP', 'ZNF-HX']","['ATRX', 'JMS', 'MRX52', 'RAD54', 'RAD54L', 'XH2', 'XNP', 'ZNF-HX']",07/24/2017
0,X,05/22/2013,54880,"[{'description': 'BCOR, BCL6 corepressor, functions with B-cell CLL/lymphoma 6 (BCL6) as a transcriptional silencer (PMID: 10898795, PMID: 16943429) and also suppresses MLLT3 (AF9) transcriptional activity (PMID: 12776190). BCOR mutations are associated with poorer outcome in patients with acute myeloid leukemia with a normal karyotype (PMID: 22012066).', 'references': [{'id': 1122, 'pubMedId': 16943429, 'title': 'Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16943429'}, {'id': 1154, 'pubMedId': 22012066, 'title': 'Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22012066'}, {'id': 1120, 'pubMedId': 10898795, 'title': 'BCoR, a novel corepressor involved in BCL-6 repression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10898795'}, {'id': 1121, 'pubMedId': 12776190, 'title': 'The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12776190'}]}]",BCOR,54880,Xp11.4,"['ANOP2', 'MAA2', 'MCOPS2']","['BCOR', 'ANOP2', 'MAA2', 'MCOPS2']",07/24/2017
0,X,05/05/2013,63035,"[{'description': 'BCORL1, BCL6 corepressor-like 1, is a transcription corepressor and is involved in histone deacetylase activity (PMID: 17379597). BCORL1 mutations have been observed in acute myeloid leukemia while elevated expression of BCORL1 has been identified in hepatocellular carcinoma (PMID: 22210327, PMID: 26879601). ', 'references': [{'id': 5454, 'pubMedId': 17379597, 'title': 'A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17379597'}, {'id': 5455, 'pubMedId': 22210327, 'title': 'The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22210327'}, {'id': 5456, 'pubMedId': 26879601, 'title': 'BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26879601'}]}]",BCORL1,63035,Xq26.1,"['BCoR-L1', 'CXorf10']","['BCORL1', 'BCoR-L1', 'CXorf10']",09/12/2017
0,7,05/26/2013,673,"[{'description': 'BRAF, v-Raf murine sarcoma viral oncogene homolog B, is a member of the Raf family of serine/threonine protein kinases, which plays a role in cell proliferation and growth (PMID: 24737949). BRAF mutations are commonly found in melanoma (PMID: 24737949).', 'references': [{'id': 131, 'pubMedId': 24737949, 'title': 'BRAF and beyond: Tailoring strategies for the individual melanoma patient.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24737949'}]}]",BRAF,673,7q34,"['B-raf', 'B-RAF1', 'BRAF1', 'NS7', 'RAFB1']","['BRAF', 'B-raf', 'B-RAF1', 'BRAF1', 'NS7', 'RAFB1']",08/17/2017
0,17,05/26/2013,672,"[{'description': 'BRCA1 is a tumor suppressor involved in the DNA damage response and DNA repair. BRCA1 germline mutations increase the risk of developing ovarian and/or breast cancer (PMID: 21285145) and somatic mutations are highest in NSCLC, pancreatic, and colon cancers (PMID: 27283171).', 'references': [{'id': 132, 'pubMedId': 21285145, 'title': 'Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21285145'}, {'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}]}]",BRCA1,672,17q21.31,"['BRCAI', 'BRCC1', 'BROVCA1', 'FANCS', 'IRIS', 'PNCA4', 'PPP1R53', 'PSCP', 'RNF53']","['BRCA1', 'BRCAI', 'BRCC1', 'BROVCA1', 'FANCS', 'IRIS', 'PNCA4', 'PPP1R53', 'PSCP', 'RNF53']",07/24/2017
0,13,05/26/2013,675,"[{'description': 'BRCA2 is a tumor suppressor involved in the homologous recombination pathway for double-strand DNA repair. BRCA2 germline mutations increase the risk of developing ovarian and/or breast cancer (PMID: 23364291) and somatic mutations are highest in colon, NSCLC, and ovarian cancers (PMID: 27283171).', 'references': [{'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}, {'id': 114, 'pubMedId': 23364291, 'title': 'BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23364291'}]}]",BRCA2,675,13q13.1,"['BRCC2', 'BROVCA2', 'FACD', 'FAD', 'FAD1', 'FANCD', 'FANCD1', 'GLM3', 'PNCA2', 'XRCC11']","['BRCA2', 'BRCC2', 'BROVCA2', 'FACD', 'FAD', 'FAD1', 'FANCD', 'FANCD1', 'GLM3', 'PNCA2', 'XRCC11']",07/24/2017
0,19,05/25/2013,811,"[{'description': 'CALR, calreticulin, encodes for a Ca(2+) chaperone protein that is primarily located in the endoplasmic reticulum. CALR frameshift mutations have been identified in essential thrombocytothemia and myelofibrosis (PMID: 24365789). ', 'references': [{'id': 3952, 'pubMedId': 24365789, 'title': 'Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24365789'}]}]",CALR,811,19p13.13,"['cC1qR', 'CRT', 'HEL-S-99n', 'RO', 'SSA']","['CALR', 'cC1qR', 'CRT', 'HEL-S-99n', 'RO', 'SSA']",07/24/2017
0,11,05/26/2013,867,"[{'description': 'CBL, Cbl proto-oncogene, E3 ubiquitin protein ligase, is an E3 ubiquitin-protein ligase involved in cell signaling and ubiquitination of tyrosine kinases (PMID: 23085373). Loss-of-function mutations in CBL result in increased tyrosine kinase signaling and oncogenic transformation, which may be responsive to FLT3 inhibitors (PMID: 23085373, PMID: 22990016).', 'references': [{'id': 133, 'pubMedId': 23085373, 'title': 'Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23085373'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]}]",CBL,867,11q23.3,"['C-CBL', 'CBL2', 'FRA11B', 'NSLL', 'RNF55']","['CBL', 'C-CBL', 'CBL2', 'FRA11B', 'NSLL', 'RNF55']",07/24/2017
0,3,05/26/2013,868,"[{'description': 'CBLB, Cbl proto-oncogene B, is an ubiquitin ligase that negatively regulates receptor tyrosine kinase signaling through targeted degradation of active kinases (PMID: 25477533). CBLB is a key regulator of immune system and loss of CBLB in mouse models results in increased anti-tumor immunity (PMID: 25477533).', 'references': [{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}]}]",CBLB,868,3q13.11,"['Cbl-b', 'Nbla00127', 'RNF56']","['CBLB', 'Cbl-b', 'Nbla00127', 'RNF56']",07/24/2017
0,19,05/25/2013,23624,"[{'description': 'CBLC, Cbl proto-oncogene C, is an ubiquitin ligase that targets activated receptor kinases for degradation (PMID: 10362357). CBLC is identified as a potential diagnostic marker for lung cancers (PMID: 17671213).', 'references': [{'id': 5589, 'pubMedId': 10362357, 'title': 'cbl-3: a new mammalian cbl family protein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10362357'}, {'id': 5590, 'pubMedId': 17671213, 'title': 'Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17671213'}]}]",CBLC,23624,19q13.32,"['CBL-3', 'CBL-SL', 'RNF57']","['CBLC', 'CBL-3', 'CBL-SL', 'RNF57']",07/24/2017
0,16,05/26/2013,999,"[{'description': 'CDH1, cadherin 1, type 1, encodes E-Cadherin and is involved in epithelial cell-cell adhesion, cell signaling, differentiation, and polarity (PMID: 18726070, PMID: 26674224). CDH1 germline mutations are associated with hereditary diffuse gastric cancer and somatic mutations are found in gastric, breast, colon, and NSCLC cancers (PMID: 27283171, PMID: 25184143).', 'references': [{'id': 4194, 'pubMedId': 25184143, 'title': 'E-cadherin and gastric cancer: cause, consequence, and applications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25184143'}, {'id': 4192, 'pubMedId': 26674224, 'title': 'CDH1/E-cadherin and solid tumors. An updated gene-disease association analysis using bioinformatics tools.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26674224'}, {'id': 4193, 'pubMedId': 18726070, 'title': 'The cell-cell adhesion molecule E-cadherin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18726070'}, {'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}]}]",CDH1,999,16q22.1,"['Arc-1', 'BCDS1', 'CD324', 'CDHE', 'ECAD', 'LCAM', 'UVO']","['CDH1', 'Arc-1', 'BCDS1', 'CD324', 'CDHE', 'ECAD', 'LCAM', 'UVO']",10/01/2017
0,9,05/26/2013,1029,"[{'description': 'CDKN2A encodes p16 and p14ARF, which inhibits Cdk4 and Cdk6  and regulates Tp53 activity to promotes cell-cycle arrest, respectively (PMID: 23875803, PMID: 17055429). CDKN2A germline mutations are associated with familial atypical multiple mole melanoma and somatic mutations are highest in pancreatic, HNSCC, NSCLC, and melanoma (PMID: 27283171).', 'references': [{'id': 138, 'pubMedId': 23875803, 'title': 'The genetics of melanoma: recent advances.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23875803'}, {'id': 6299, 'pubMedId': 27283171, 'title': 'The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283171'}, {'id': 4575, 'pubMedId': 17055429, 'title': 'The regulation of INK4/ARF in cancer and aging.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17055429'}]}]",CDKN2A,1029,9p21.3,"['ARF', 'CDK4I', 'CDKN2', 'CMM2', 'INK4', 'INK4A', 'MLM', 'MTS-1', 'MTS1', 'P14', 'P14ARF', 'P16', 'P16-INK4A', 'P16INK4', 'P16INK4A', 'P19', 'P19ARF', 'TP16']","['CDKN2A', 'ARF', 'CDK4I', 'CDKN2', 'CMM2', 'INK4', 'INK4A', 'MLM', 'MTS-1', 'MTS1', 'P14', 'P14ARF', 'P16', 'P16-INK4A', 'P16INK4', 'P16INK4A', 'P19', 'P19ARF', 'TP16']",07/24/2017
0,19,05/25/2013,1050,"[{'description': 'CEBPA, CCAAT/enhancer binding protein alpha, is a transcription factor that regulates haematopoiesis. CEBPA acts as a tumor suppressor in acute myeloid leukaemia (PMID: 26601784).', 'references': [{'id': 5328, 'pubMedId': 26601784, 'title': 'The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26601784'}]}]",CEBPA,1050,19q13.11,"['C/EBP-alpha', 'CEBP']","['CEBPA', 'C/EBP-alpha', 'CEBP']",07/24/2017
0,5,05/25/2013,1436,"[{'description': 'CSF1R, macrophage colony-stimulating factor 1 receptor, is a tyrosine kinase and receptor for CSF1 and IL34. Ligand binding to CSF1R activates PI3K-AKT-mTOR, RAS-RAF-MEK-ERK and STAT signaling pathways (PMID: 22186992).', 'references': [{'id': 139, 'pubMedId': 22186992, 'title': 'Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22186992'}]}]",CSF1R,1436,5q32,"['C-FMS', 'CD115', 'CSF-1R', 'CSFR', 'FIM2', 'FMS', 'HDLS', 'M-CSF-R']","['CSF1R', 'C-FMS', 'CD115', 'CSF-1R', 'CSFR', 'FIM2', 'FMS', 'HDLS', 'M-CSF-R']",07/24/2017
0,1,05/26/2013,1441,"[{'description': 'CSF3R, colony stimulating factor 3 receptor, encodes for a cytokine receptor involved in signaling the differentiation, production and survival of granulocytes. CSF3R mutations commonly occur in leukemias (PMID: 23896413).', 'references': [{'id': 3950, 'pubMedId': 23896413, 'title': 'The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23896413'}]}]",CSF3R,1441,1p34.3,"['CD114', 'GCSFR', 'SCN7']","['CSF3R', 'CD114', 'GCSFR', 'SCN7']",07/24/2017
0,3,05/26/2013,1499,"[{'description': 'CTNNB1, beta-catenin, is a member of the WNT signaling pathway and component of cadherin-based adherens junctions. Imbalance of beta-catenin is implicated in cancer progression and metastasis (PMID: 22617422).', 'references': [{'id': 140, 'pubMedId': 22617422, 'title': 'The many faces and functions of β-catenin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22617422'}]}]",CTNNB1,1499,3p22.1,"['armadillo', 'CTNNB', 'EVR7', 'MRD19']","['CTNNB1', 'armadillo', 'CTNNB', 'EVR7', 'MRD19']",07/24/2017
0,2,05/25/2013,1788,"[{'description': 'DNMT3A, DNA (cytosine-5)-methyltransferase 3A, plays a role in embryonic development and aberrant DNA methylation in cancer (PMID: 24649006).', 'references': [{'id': 142, 'pubMedId': 24649006, 'title': 'DNMT3A -448A>G polymorphism and the risk for hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24649006'}]}]",DNMT3A,1788,2p23.3,"['DNMT3A2', 'M.HsaIIIA', 'TBRS']","['DNMT3A', 'DNMT3A2', 'M.HsaIIIA', 'TBRS']",07/24/2017
0,7,05/26/2013,1956,"[{'description': 'EGFR (HER1), epidermal growth factor receptor, is a tyrosine kinase receptor, which activates RAS/RAF/MEK and PI3K/AKT/mTOR pathways, leading to increased cell proliferation and growth (PMID: 24312144). EGFR activating mutations are commonly found in non-small cell lung cancer (PMID: 26609494). ', 'references': [{'id': 93, 'pubMedId': 24312144, 'title': 'Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24312144'}, {'id': 5162, 'pubMedId': 26609494, 'title': 'EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26609494'}]}]",EGFR,1956,7p11.2,"['ERBB', 'ERBB1', 'HER1', 'mENA', 'NISBD2', 'PIG61']","['EGFR', 'ERBB', 'ERBB1', 'HER1', 'mENA', 'NISBD2', 'PIG61']",07/24/2017
0,2,05/12/2013,27436,"[{'description': 'EML4, echinoderm microtubule associated protein like 4, plays a role in microtubule formation. The fusion protein of EML4-ALK results in transformation activity and is present in a small percentage of patients with non-small cell lung cancer (PMID: 17625570, PMID: 23341890).', 'references': [{'id': 2146, 'pubMedId': 23341890, 'title': 'Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23341890'}, {'id': 2131, 'pubMedId': 17625570, 'title': 'Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17625570'}]}]",EML4,27436,2p21,"['C2orf2', 'ELP120', 'EMAP-4', 'EMAPL4', 'ROPP120']","['EML4', 'C2orf2', 'ELP120', 'EMAP-4', 'EMAPL4', 'ROPP120']",07/24/2017
0,17,05/26/2013,2064,"[{'description': 'ERBB2 encodes HER2, an EGFR receptor tyrosine kinase, which activates PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways. ERBB2 (HER2) amplification has been implicated in several tumor types (PMID: 17471238).', 'references': [{'id': 145, 'pubMedId': 17471238, 'title': 'The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17471238'}]}]",ERBB2,2064,17q12,"['CD340', 'HER-2', 'HER-2/neu', 'HER2', 'MLN 19', 'NEU', 'NGL', 'TKR1']","['ERBB2', 'CD340', 'HER-2', 'HER-2/neu', 'HER2', 'MLN 19', 'NEU', 'NGL', 'TKR1']",07/24/2017
0,2,05/25/2013,2066,"[{'description': 'ERBB4 encodes HER4, an EGFR receptor tyrosine kinase, which activates PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways to promote cell survival and proliferation (PMID:17471238).', 'references': [{'id': 145, 'pubMedId': 17471238, 'title': 'The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17471238'}]}]",ERBB4,2066,2q34,"['ALS19', 'HER4', 'p180erbB4']","['ERBB4', 'ALS19', 'HER4', 'p180erbB4']",07/24/2017
0,12,05/25/2013,2120,"[{'description': 'ETV6, ets variant 6, is a member of the ETS family of transcription factors, which functions as a transcriptional repressor and is involved in hematopoietic differentiation (PMID: 16828711). Fusions of ETV6 with various partners are frequently associated with hematological cancers (PMID: 22528774).', 'references': [{'id': 1203, 'pubMedId': 16828711, 'title': 'TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16828711'}, {'id': 6331, 'pubMedId': 22578774, 'title': 'ETV6 fusion genes in hematological malignancies: a review.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22578774'}]}]",ETV6,2120,12p13.2,"['TEL', 'TEL/ABL', 'THC5']","['ETV6', 'TEL', 'TEL/ABL', 'THC5']",07/24/2017
0,7,05/22/2013,2146,"[{'description': 'EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit, encodes the catalytic subunit of the polycomb repressive complex 2 and represses transcription of a number of tumor suppressor genes (PMID: 24362326).', 'references': [{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}]}]",EZH2,2146,7q36.1,"['ENX-1', 'ENX1', 'EZH2b', 'KMT6', 'KMT6A', 'WVS', 'WVS2']","['EZH2', 'ENX-1', 'ENX1', 'EZH2b', 'KMT6', 'KMT6A', 'WVS', 'WVS2']",07/24/2017
0,4,05/25/2013,55294,"[{'description': 'FBXW7, F-box/WD repeat-containing protein 7, is part of the SCF E3 ubiquitin-protein ligase complex. FBXW7 participates in the degradation of a variety of oncoproteins and is deleted or mutated in many cancers (PMID: 22673505), including colorectal (PMID: 28424412).', 'references': [{'id': 152, 'pubMedId': 22673505, 'title': 'Tumor suppressor functions of FBW7 in cancer development and progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22673505'}, {'id': 9937, 'pubMedId': 28424412, 'title': 'FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424412'}]}]",FBXW7,55294,4q31.3,"['AGO', 'CDC4', 'FBW6', 'FBW7', 'FBX30', 'FBXO30', 'FBXW6', 'hAgo', 'hCdc4', 'SEL-10', 'SEL10']","['FBXW7', 'AGO', 'CDC4', 'FBW6', 'FBW7', 'FBX30', 'FBXO30', 'FBXW6', 'hAgo', 'hCdc4', 'SEL-10', 'SEL10']",09/18/2017
0,8,05/25/2013,2260,"[{'description': 'FGFR1 is a receptor tyrosine kinase activated upon binding of the FGF ligand, which activates RAS-MAPK and PI3K-AKT pathways.  Altered function of FGFR1 in cancer may lead to increased cell proliferation and decreased apoptosis (PMID: 22508544).', 'references': [{'id': 153, 'pubMedId': 22508544, 'title': 'Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22508544'}]}]",FGFR1,2260,8p11.23,"['bFGF-R-1', 'BFGFR', 'CD331', 'CEK', 'ECCL', 'FGFBR', 'FGFR-1', 'FLG', 'FLT-2', 'FLT2', 'HBGFR', 'HH2', 'HRTFDS', 'KAL2', 'N-SAM', 'OGD']","['FGFR1', 'bFGF-R-1', 'BFGFR', 'CD331', 'CEK', 'ECCL', 'FGFBR', 'FGFR-1', 'FLG', 'FLT-2', 'FLT2', 'HBGFR', 'HH2', 'HRTFDS', 'KAL2', 'N-SAM', 'OGD']",07/24/2017
0,10,05/25/2013,2263,"[{'description': 'FGFR2 is a receptor tyrosine kinase activated upon binding of the FGF ligand, which activates RAS-MAPK and PI3K-AKT pathways.  Altered function of FGFR2 in cancer may lead to increased cell proliferation and decreased apoptosis (PMID: 22508544).', 'references': [{'id': 153, 'pubMedId': 22508544, 'title': 'Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22508544'}]}]",FGFR2,2263,10q26.13,"['BBDS', 'BEK', 'BFR-1', 'CD332', 'CEK3', 'CFD1', 'ECT1', 'JWS', 'K-SAM', 'KGFR', 'TK14', 'TK25']","['FGFR2', 'BBDS', 'BEK', 'BFR-1', 'CD332', 'CEK3', 'CFD1', 'ECT1', 'JWS', 'K-SAM', 'KGFR', 'TK14', 'TK25']",07/24/2017
0,4,05/26/2013,2261,"[{'description': 'FGFR3 is a receptor tyrosine kinase activated upon binding of the FGF ligand, which activates RAS-MAPK and PI3K-AKT pathways.  Altered function of FGFR3 in cancer may lead to increased cell proliferation and decreased apoptosis (PMID: 22508544).', 'references': [{'id': 153, 'pubMedId': 22508544, 'title': 'Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22508544'}]}]",FGFR3,2261,4p16.3,"['ACH', 'CD333', 'CEK2', 'HSFGFR3EX', 'JTK4']","['FGFR3', 'ACH', 'CD333', 'CEK2', 'HSFGFR3EX', 'JTK4']",07/24/2017
0,13,05/26/2013,2322,"[{'description': 'FLT3, receptor-type tyrosine-protein kinase FLT3, is involved in differentiation, proliferation, and survival of hematopoietic progenitor cells.  Activating mutations of FLT3 are common in hematologic tumors (PMID: 19467916).', 'references': [{'id': 154, 'pubMedId': 19467916, 'title': 'FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19467916'}]}]",FLT3,2322,13q12.2,"['CD135', 'FLK-2', 'FLK2', 'STK1']","['FLT3', 'CD135', 'FLK-2', 'FLK2', 'STK1']",07/24/2017
0,3,05/22/2013,668,"[{'description': 'FOXL2, forkhead box L2, encodes for a transcription factor that is a member of the forked-winged helix family and plays a role in ovary development (PMID: 21640373). FOXL2 is commonly mutated in granulosa-cell tumors (PMID: 19956657).', 'references': [{'id': 762, 'pubMedId': 19956657, 'title': 'The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19956657'}, {'id': 9321, 'pubMedId': 21640373, 'title': 'FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21640373'}]}]",FOXL2,668,3q22.3,"['BPES', 'BPES1', 'PFRK', 'PINTO', 'POF3']","['FOXL2', 'BPES', 'BPES1', 'PFRK', 'PINTO', 'POF3']",07/24/2017
0,X,05/26/2013,2623,"[{'description': 'GATA1, GATA binding protein 1, is a transcriptional activator or repressor, which plays a role in erythroid development. GATA1 mutations are associated with Down Syndrome preleukemia and leukemia (PMID: 25435116; PMID: 24880866).', 'references': [{'id': 1276, 'pubMedId': 25435116, 'title': 'Down syndrome preleukemia and leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25435116'}, {'id': 1277, 'pubMedId': 24880866, 'title': 'Are GATA1 mutations occurring at random in Down syndrome transient leukemia?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24880866'}]}]",GATA1,2623,Xp11.23,"['ERYF1', 'GATA-1', 'GF-1', 'GF1', 'NF-E1', 'NFE1', 'XLANP', 'XLTDA', 'XLTT']","['GATA1', 'ERYF1', 'GATA-1', 'GF-1', 'GF1', 'NF-E1', 'NFE1', 'XLANP', 'XLTDA', 'XLTT']",07/24/2017
0,3,05/22/2013,2624,"[{'description': 'GATA2, GATA binding protein 2, is a zinc-finger transcription factor that plays a central role in regulating the proliferation and survival of hematopoietic stem cells (PMID: 22192845). Mutations in GATA2 are associated with myelodysplastic syndrome and leukemia (PMID: 22192845).', 'references': [{'id': 1240, 'pubMedId': 22192845, 'title': 'GATA-2 mediated regulation of normal hematopoietic stem/progenitor cell function, myelodysplasia and myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22192845'}]}]",GATA2,2624,3q21.3,"['DCML', 'IMD21', 'MONOMAC', 'NFE1B']","['GATA2', 'DCML', 'IMD21', 'MONOMAC', 'NFE1B']",07/24/2017
0,19,05/25/2013,2767,"[{'description': 'GNA11, G protein subunit alpha 11, is a guanine nucleotide-binding protein (G protein) subunit, which is activated following ligand binding to G-protein coupled receptors and functions in cell signaling (PMID: 27148356). GNA11 hotspot mutations impair intrinsic GTPase activity, resulting in constitutive pathway activation and are common in uveal melanoma (PMID: 23640210, PMID: 27148356).', 'references': [{'id': 253, 'pubMedId': 23640210, 'title': 'The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23640210'}, {'id': 8754, 'pubMedId': 27148356, 'title': 'Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27148356'}]}]",GNA11,2767,19p13.3,"['FBH', 'FBH2', 'FHH2', 'GNA-11', 'HHC2', 'HYPOC2']","['GNA11', 'FBH', 'FBH2', 'FHH2', 'GNA-11', 'HHC2', 'HYPOC2']",07/24/2017
0,9,05/25/2013,2776,"[{'description': 'GNAQ, G protein subunit alpha q, is a guanine-binding protein (G protein) subunit, which is activated following ligand binding to G-protein coupled receptors and functions in cell signaling (PMID: 27148356). GNAQ hotspot mutations impair intrinsic GTPase activity, resulting in constitutive pathway activation and are common in uveal melanoma (PMID: 23640210, PMID: 27148356).', 'references': [{'id': 253, 'pubMedId': 23640210, 'title': 'The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23640210'}, {'id': 8754, 'pubMedId': 27148356, 'title': 'Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27148356'}]}]",GNAQ,2776,9q21.2,"['CMC1', 'G-ALPHA-q', 'GAQ', 'SWS']","['GNAQ', 'CMC1', 'G-ALPHA-q', 'GAQ', 'SWS']",07/24/2017
0,20,05/25/2013,2778,"[{'description': 'GNAS, GNAS complex locus, is a GTPase that is activated upon ligand binding of a G-protein coupled receptor, and is involved in mediating hormone response (PMID: 23640210, PMID: 25851935). Hotspot mutations impair GTPase activity, resulting in constitutive pathway activation and are common in a variety of tumor types (PMID: 23640210).', 'references': [{'id': 253, 'pubMedId': 23640210, 'title': 'The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23640210'}, {'id': 6283, 'pubMedId': 25851935, 'title': 'GNAS Spectrum of Disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25851935'}]}]",GNAS,2778,20q13.32,"['AHO', 'C20orf45', 'GNAS1', 'GPSA', 'GSA', 'GSP', 'NESP', 'PITA3', 'POH', 'SCG6', 'SgVI']","['GNAS', 'AHO', 'C20orf45', 'GNAS1', 'GPSA', 'GSA', 'GSP', 'NESP', 'PITA3', 'POH', 'SCG6', 'SgVI']",10/10/2017
0,12,05/29/2013,6927,"[{'description': 'HNF1A, HNF1 homeobox A, is a transcription factor that regulates gene expression in the liver, pancreas, intestine, and kidney, and alterations in HNF1A pathway signaling are associated with pancreatic tumors and hepatic adenomas (PMID: 25233928, PMID: 25076298).', 'references': [{'id': 1344, 'pubMedId': 25233928, 'title': 'Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25233928'}, {'id': 4196, 'pubMedId': 25076298, 'title': 'Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25076298'}]}]",HNF1A,6927,12q24.31,"['HNF-1A', 'HNF1', 'IDDM20', 'LFB1', 'MODY3', 'TCF-1', 'TCF1']","['HNF1A', 'HNF-1A', 'HNF1', 'IDDM20', 'LFB1', 'MODY3', 'TCF-1', 'TCF1']",07/24/2017
0,11,05/26/2013,3265,"[{'description': 'HRAS encodes transforming protein 21, which has intrinsic GTPase activity.  HRAS activation by growth factors stimulates multiple effector pathways such as RAF and PI3K to promote cell proliferation (PMID: 21779504). ', 'references': [{'id': 117, 'pubMedId': 21779504, 'title': 'Ras in cancer and developmental diseases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21779504'}]}]",HRAS,3265,11p15.5,"['C-BAS/HAS', 'C-H-RAS', 'C-HA-RAS1', 'CTLO', 'H-RASIDX', 'HAMSV', 'HRAS1', 'p21ras', 'RASH1']","['HRAS', 'C-BAS/HAS', 'C-H-RAS', 'C-HA-RAS1', 'CTLO', 'H-RASIDX', 'HAMSV', 'HRAS1', 'p21ras', 'RASH1']",07/24/2017
0,2,05/26/2013,3417,"[{'description': 'IDH1, isocitrate dehydrogenase [NADP] cytoplasmic, catalyzes the conversion of isocitrate to alpha-ketoglutarate (alpha-KG). Mutations in IDH1 convert alpha-KG to 2-HG, which is an oncogenic metabolite (PMID: 23999441). ', 'references': [{'id': 255, 'pubMedId': 23999441, 'title': 'Isocitrate dehydrogenase mutations in leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23999441'}]}]",IDH1,3417,2q34,"['HEL-216', 'HEL-S-26', 'IDCD', 'IDH', 'IDP', 'IDPC', 'PICD']","['IDH1', 'HEL-216', 'HEL-S-26', 'IDCD', 'IDH', 'IDP', 'IDPC', 'PICD']",09/14/2017
0,15,05/26/2013,3418,"[{'description': 'IDH2, isocitrate dehydrogenase [NADP] mitochondrial, catalyzes the conversion of isocitrate to alpha-ketoglutarate (alpha-KG). Mutations in IDH2 convert alpha-KG to 2-HG, which is an oncogenic metabolite (PMID: 23999441). ', 'references': [{'id': 255, 'pubMedId': 23999441, 'title': 'Isocitrate dehydrogenase mutations in leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23999441'}]}]",IDH2,3418,15q26.1,"['D2HGA2', 'ICD-M', 'IDH', 'IDHM', 'IDP', 'IDPM', 'mNADP-IDH']","['IDH2', 'D2HGA2', 'ICD-M', 'IDH', 'IDHM', 'IDP', 'IDPM', 'mNADP-IDH']",07/24/2017
0,7,05/26/2013,10320,"[{'description': 'IKZF1, IKAROS family zinc finger 1 (Ikaros), is a zinc finger transcription factor that regulates hematopoietic differentiation and immune system development, and functions as a tumor suppressor (PMID: 24659638, PMID: 22150303). Mutations in IKZF1 are associated with acute lymphoblastic leukemia (PMID: 24659638, PMID: 22150303).\r\n', 'references': [{'id': 1435, 'pubMedId': 22150303, 'title': 'Ikaros and tumor suppression in acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22150303'}, {'id': 1434, 'pubMedId': 24659638, 'title': 'Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia - the role of Ikaros.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24659638'}]}]",IKZF1,10320,7p12.2,"['CVID13', 'Hs.54452', 'IK1', 'IKAROS', 'LyF-1', 'LYF1', 'PPP1R92', 'PRO0758', 'ZNFN1A1']","['IKZF1', 'CVID13', 'Hs.54452', 'IK1', 'IKAROS', 'LyF-1', 'LYF1', 'PPP1R92', 'PRO0758', 'ZNFN1A1']",07/24/2017
0,9,05/26/2013,3717,"[{'description': 'JAK2, janus kinase 2, is a non-receptor protein tyrosine kinase involved in the interferon-alpha/beta/gamma pathway and is a member of the JAK/STAT signaling pathway (PMID: 15575979).', 'references': [{'id': 257, 'pubMedId': 15575979, 'title': 'The Janus kinases (Jaks).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15575979'}]}]",JAK2,3717,9p24.1,"['JTK10', 'THCYT3']","['JAK2', 'JTK10', 'THCYT3']",07/24/2017
0,19,05/25/2013,3718,"[{'description': 'JAK3, janus kinase 3, is a non-receptor protein tyrosine kinase involved in the interferon-alpha/beta/gamma pathway and is a member of the JAK/STAT signaling pathway (PMID: 15575979).', 'references': [{'id': 257, 'pubMedId': 15575979, 'title': 'The Janus kinases (Jaks).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15575979'}]}]",JAK3,3718,19p13.11,"['JAK-3', 'JAK3_HUMAN', 'JAKL', 'L-JAK', 'LJAK']","['JAK3', 'JAK-3', 'JAK3_HUMAN', 'JAKL', 'L-JAK', 'LJAK']",07/24/2017
0,X,05/22/2013,7403,"[{'description': 'KDM6A, lysine (K)-specific demethylase 6A, is a Jumonji domain histone demethylase, regulating gene transcription through chromatin remodeling to affect cell growth and differentiation. KDM6A altered expression have been reported in HNSCC and bladder cancers (PMID: 25275298, PMID: 25225064).', 'references': [{'id': 1586, 'pubMedId': 25275298, 'title': 'The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25275298'}, {'id': 1593, 'pubMedId': 25225064, 'title': 'Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25225064'}]}]",KDM6A,7403,Xp11.3,"['bA386N14.2', 'KABUK2', 'UTX']","['KDM6A', 'bA386N14.2', 'KABUK2', 'UTX']",07/24/2017
0,4,05/26/2013,3791,"[{'description': 'KDR, Kinase insert domain receptor, encodes Vegfr2, a receptor tyrosine kinase overexpressed in a variety of solid tumors (PMID: 20606037).  ', 'references': [{'id': 19, 'pubMedId': 20606037, 'title': 'Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20606037'}]}]",KDR,3791,4q12,"['CD309', 'FLK1', 'VEGFR', 'VEGFR2']","['KDR', 'CD309', 'FLK1', 'VEGFR', 'VEGFR2']",07/24/2017
0,4,05/25/2013,3815,"[{'description': 'KIT (c-KIT), mast/stem cell growth factor receptor Kit, is a receptor tyrosine kinase, which activates PI3K, JAK/STAT, and MAPK pathways to promote cell survival and proliferation (PMID: 23181448).', 'references': [{'id': 258, 'pubMedId': 23181448, 'title': 'Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23181448'}]}]",KIT,3815,4q12,"['C-Kit', 'CD117', 'PBT', 'SCFR']","['KIT', 'C-Kit', 'CD117', 'PBT', 'SCFR']",07/24/2017
0,11,05/26/2013,4297,"[{'description': 'KMT2A, lysine methyltransferase 2A, also referred to as MLL, is a transcriptional coactivator that epigenetically regulates gene transcription via methylation and is primarily associated with hematopoietic and embyronic development (PMID: 26161385). KMT2A translocations are frequently observed in specific leukemias including acute myeloid, acute lymphoblastic, and mixed lineage (PMID: 17957188). ', 'references': [{'id': 5468, 'pubMedId': 26161385, 'title': 'Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26161385'}, {'id': 5469, 'pubMedId': 17957188, 'title': 'MLL translocations, histone modifications and leukaemia stem-cell development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17957188'}]}]",KMT2A,4297,11q23.3,"['ALL-1', 'CXXC7', 'HRX', 'HTRX1', 'MLL', 'MLL1', 'MLL1A', 'TRX1', 'WDSTS']","['KMT2A', 'ALL-1', 'CXXC7', 'HRX', 'HTRX1', 'MLL', 'MLL1', 'MLL1A', 'TRX1', 'WDSTS']",07/25/2017
0,12,05/26/2013,3845,"[{'description': 'KRAS is a member of the small GTPase superfamily and a key regulator of the MAPK, PI3K/AKT/mTOR pathways (PMID: 23622131).', 'references': [{'id': 208, 'pubMedId': 23622131, 'title': 'Roles for KRAS in pancreatic tumor development and progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23622131'}]}]",KRAS,3845,12p12.1,"['C-K-RAS', 'c-Ki-ras2', 'CFC2', 'K-Ras', 'K-RAS2A', 'K-RAS2B', 'K-RAS4A', 'K-RAS4B', 'KI-RAS', 'KRAS1', 'KRAS2', 'NS', 'NS3', 'RALD', 'RASK2']","['KRAS', 'C-K-RAS', 'c-Ki-ras2', 'CFC2', 'K-Ras', 'K-RAS2A', 'K-RAS2B', 'K-RAS4A', 'K-RAS4B', 'KI-RAS', 'KRAS1', 'KRAS2', 'NS', 'NS3', 'RALD', 'RASK2']",08/11/2017
0,15,05/25/2013,5604,"[{'description': 'MAP2K1 (MEK1), mitogen-activated protein kinase kinase 1, is a serine-threonine kinase, which activates that RAS-RAF-MEK-ERK pathway in cell proliferation and differentiation (PMID: 22753777).', 'references': [{'id': 259, 'pubMedId': 22753777, 'title': 'MEK genomics in development and disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753777'}]}]",MAP2K1,5604,15q22.31,"['CFC3', 'MAPKK1', 'MEK1', 'MKK1', 'PRKMK1']","['MAP2K1', 'CFC3', 'MAPKK1', 'MEK1', 'MKK1', 'PRKMK1']",07/24/2017
0,7,05/26/2013,4233,"[{'description': 'MET (c-MET), hepatocyte growth factor receptor, is a receptor tyrosine kinase, which activates MAPK, PI3K/AKT, SRC, and STAT pathways to promote cell proliferation, invasion and angiogenesis (PMID: 22128285). MET mutations have been identified in a variety of human cancers (PMID: 28603720).', 'references': [{'id': 9803, 'pubMedId': 28603720, 'title': 'MET in human cancer: germline and somatic mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28603720'}, {'id': 262, 'pubMedId': 22128285, 'title': 'c-MET as a potential therapeutic target and biomarker in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22128285'}]}]",MET,4233,7q31.2,"['AUTS9', 'c-Met', 'DFNB97', 'HGFR', 'RCCP2']","['MET', 'AUTS9', 'c-Met', 'DFNB97', 'HGFR', 'RCCP2']",08/28/2017
0,3,05/26/2013,4292,"[{'description': 'MLH1, MutL protein homolog 1, is a tumor suppressor that dimerizes with Pms2 to form a component of the DNA mismatch repair (MMR) system (PMID: 16873062). MLH1 promoter hypermethylation, resulting in Mlh1 deficiency, is frequently associated with sporadic colorectal, gastric, and esophageal cancers (PMID: 23555617, PMID: 21988782, PMID: 28224663, PMID: 28454461).', 'references': [{'id': 9237, 'pubMedId': 28224663, 'title': 'Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28224663'}, {'id': 3310, 'pubMedId': 23555617, 'title': 'MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23555617'}, {'id': 3311, 'pubMedId': 16873062, 'title': 'Endonucleolytic function of MutLalpha in human mismatch repair.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16873062'}, {'id': 3309, 'pubMedId': 21988782, 'title': 'A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21988782'}]}]",MLH1,4292,3p22.2,"['COCA2', 'FCC2', 'hMLH1', 'HNPCC', 'HNPCC2']","['MLH1', 'COCA2', 'FCC2', 'hMLH1', 'HNPCC', 'HNPCC2']",07/24/2017
0,1,05/29/2013,4352,"[{'description': 'MPL, MPL proto-oncogene, thrombopoietin receptor, associates with JAK2 and TYK2 to activate several signal transduction pathways to control blood cell development (PMID: 16834459). MPL mutations are often found in myeloproliferative neoplasms (PMID: 27727468).', 'references': [{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}, {'id': 9804, 'pubMedId': 27727468, 'title': 'Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27727468'}]}]",MPL,4352,1p34.2,"['C-MPL', 'CD110', 'MPLV', 'THCYT2', 'TPOR']","['MPL', 'C-MPL', 'CD110', 'MPLV', 'THCYT2', 'TPOR']",08/28/2017
0,2,05/26/2013,2956,"[{'description': 'MSH6, mutS homolog 6, binds with Msh2 to form the MutS-alpha complex, which functions in initiation of the DNA mismatch repair system (PMID: 23391514). Mutations in MSH6 are associated with susceptibility to colon cancer and endometrial cancer (PMID: 20028993)', 'references': [{'id': 1519, 'pubMedId': 23391514, 'title': 'Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23391514'}, {'id': 1520, 'pubMedId': 20028993, 'title': 'Risks of Lynch syndrome cancers for MSH6 mutation carriers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028993'}]}]",MSH6,2956,2p16.3,"['GTBP', 'GTMBP', 'HNPCC5', 'HSAP', 'p160']","['MSH6', 'GTBP', 'GTMBP', 'HNPCC5', 'HSAP', 'p160']",07/24/2017
0,3,05/25/2013,4615,"[{'description': 'MYD88, myeloid differentiation primary response protein, is an adapter protein involved in Toll-like receptor and IL-1 signaling in the immune response, cytokine secretion, and inflammatory response (PMID: 19506249). MYD88 mutations are frequently identified in hematological malignancies (PMID: 25132836).', 'references': [{'id': 266, 'pubMedId': 19506249, 'title': 'Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19506249'}, {'id': 9813, 'pubMedId': 25132836, 'title': 'Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25132836'}]}]",MYD88,4615,3p22.2,['MYD88D'],"['MYD88', 'MYD88D']",08/28/2017
0,9,05/26/2013,4851,"[{'description': 'NOTCH1, notch 1, is a transmembrane receptor, which plays a role in cell fate determination, growth, and survival (PMID: 25388163). Activating Notch1 mutations are common in T-cell lymphoblastic leukemia/lymphoma (PMID: 22006338).', 'references': [{'id': 269, 'pubMedId': 22006338, 'title': 'Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22006338'}, {'id': 4517, 'pubMedId': 25388163, 'title': 'Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25388163'}]}]",NOTCH1,4851,9q34.3,"['AOS5', 'AOVD1', 'hN1', 'TAN1']","['NOTCH1', 'AOS5', 'AOVD1', 'hN1', 'TAN1']",08/30/2017
0,5,05/26/2013,4869,"[{'description': 'NPM1, nucleophosmin (nucleolar phosphoprotein B23, numatrin), is a multifunctional phosphoprotein that shuttles between the nucleus and cytoplasm and is involved in ribosomal processing and export, chromatin remodeling, DNA replication and repair, cell cycle control and molecular chaperoning. Mutation of NPM1 accounts for one third of adult acute myeloid leukemia (PMID: 23436734). ', 'references': [{'id': 1521, 'pubMedId': 23436734, 'title': 'Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23436734'}]}]",NPM1,4869,5q35.1,"['B23', 'NPM']","['NPM1', 'B23', 'NPM']",07/24/2017
0,1,05/25/2013,4893,"[{'description': 'NRAS, NRAS proto-oncogene, GTPase, encodes neuroblastoma RAS viral (v-ras) oncogene homolog, which has intrinsic GTPase activity (PMID: 24077403). NRAS activation by growth factors stimulates multiple effector pathways such as RAF and PI3K to promote cell proliferation, and NRAS mutations have been observed in melanoma (PMID: 24077403). ', 'references': [{'id': 116, 'pubMedId': 24077403, 'title': 'Melanoma mutagenesis and aberrant cell signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24077403'}]}]",NRAS,4893,1p13.2,"['ALPS4', 'CMNS', 'N-ras', 'NCMS', 'NRAS1', 'NS6']","['NRAS', 'ALPS4', 'CMNS', 'N-ras', 'NCMS', 'NRAS1', 'NS6']",10/13/2017
0,4,05/26/2013,5156,"[{'description': 'PDGFRA, platelet-derived growth factor receptor alpha, is a receptor tyrosine kinase, which activates PI3K/Akt, RAS/MAPK, and JAK/STAT pathways to promote cell proliferation and survival (PMID: 21605429).', 'references': [{'id': 271, 'pubMedId': 21605429, 'title': 'The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21605429'}]}]",PDGFRA,5156,4q12,"['CD140A', 'PDGFR-2', 'PDGFR2']","['PDGFRA', 'CD140A', 'PDGFR-2', 'PDGFR2']",07/24/2017
0,X,05/22/2013,84295,"[{'description': 'PHF6, PHD finger protein 6, encodes a transcriptional repressor that plays a role in cell cycle regulation via suppression of rRNA transcription (PMID: 23229552). PHF6 inactivating mutations have been observed in acute lymphocytic leukemia (PMID: 20228800). ', 'references': [{'id': 5543, 'pubMedId': 23229552, 'title': 'PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23229552'}, {'id': 5544, 'pubMedId': 20228800, 'title': 'PHF6 mutations in T-cell acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20228800'}]}]",PHF6,84295,Xq26.2,"['BFLS', 'BORJ', 'CENP-31']","['PHF6', 'BFLS', 'BORJ', 'CENP-31']",07/24/2017
0,3,05/26/2013,5290,"[{'description': 'PIK3CA, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, activates AKT/mTOR signaling to promote cell proliferation (PMID: 23411347). ', 'references': [{'id': 273, 'pubMedId': 23411347, 'title': 'Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23411347'}]}]",PIK3CA,5290,3q26.32,"['CLOVE', 'CWS5', 'MCAP', 'MCM', 'MCMTC', 'p110-alpha', 'PI3K', 'PI3K-alpha']","['PIK3CA', 'CLOVE', 'CWS5', 'MCAP', 'MCM', 'MCMTC', 'p110-alpha', 'PI3K', 'PI3K-alpha']",07/24/2017
0,10,05/26/2013,5728,"[{'description': 'PTEN, phosphatase and tensin homolog, is a tumor suppressor with roles in the cell cycle, growth, DNA repair, cell survival and regulation of the AKT-mTOR pathway (PMID: 24656806). PTEN alterations resulting in loss of function have been found in many types of cancer including, but not limited to endometrial, skin, and prostate (PMID: 18767981).', 'references': [{'id': 276, 'pubMedId': 24656806, 'title': 'PTEN function: the long and the short of it.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24656806'}, {'id': 8789, 'pubMedId': 18767981, 'title': 'PTEN and the PI3-kinase pathway in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18767981'}]}]",PTEN,5728,10q23.31,"['10q23del', 'BZS', 'CWS1', 'DEC', 'GLM2', 'MHAM', 'MMAC1', 'PTEN1', 'PTENbeta', 'TEP1']","['PTEN', '10q23del', 'BZS', 'CWS1', 'DEC', 'GLM2', 'MHAM', 'MMAC1', 'PTEN1', 'PTENbeta', 'TEP1']",07/24/2017
0,12,05/25/2013,5781,"[{'description': 'PTPN11, protein tyrosine phosphatase, non-receptor type 11, is a regulator of growth factor signaling and has been characterized as both an oncogene and tumor suppressor (PMID: 20337577).', 'references': [{'id': 277, 'pubMedId': 20337577, 'title': 'Targeting protein tyrosine phosphatases for anticancer drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20337577'}]}]",PTPN11,5781,12q24.13,"['BPTP3', 'CFC', 'JMML', 'METCDS', 'NS1', 'PTP-1D', 'PTP2C', 'SH-PTP2', 'SH-PTP3', 'SHP2']","['PTPN11', 'BPTP3', 'CFC', 'JMML', 'METCDS', 'NS1', 'PTP-1D', 'PTP2C', 'SH-PTP2', 'SH-PTP3', 'SHP2']",07/24/2017
0,8,05/25/2013,5885,"[{'description': 'RAD21, RAD21 cohesin complex component, is a member of the cohesion complex, which is responsible for maintaining sister chromatid segregation during the S-phase of the mitotic cycle (PMID: 22145905). Amplification and over expression of RAD21 has been observed in several cancer types including breast, prostate, and colorectal (PMID: 21255398, PMID: 24548858). ', 'references': [{'id': 5643, 'pubMedId': 24548858, 'title': 'RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24548858'}, {'id': 5641, 'pubMedId': 22145905, 'title': 'A cohesin-RAD21 interactome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22145905'}, {'id': 5642, 'pubMedId': 21255398, 'title': 'Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21255398'}]}]",RAD21,5885,8q24.11,"['CDLS4', 'hHR21', 'HR21', 'HRAD21', 'MCD1', 'NXP1', 'SCC1']","['RAD21', 'CDLS4', 'hHR21', 'HR21', 'HRAD21', 'MCD1', 'NXP1', 'SCC1']",07/24/2017
0,13,05/29/2013,5925,"[{'description': 'RB1, retinoblastoma 1, is a key negative regulator of the G1 to S transition during cell division (PMID: 15084261). Inactivation of Rb1 and loss of Rb1 tumor suppressor function has been identified in many early stage cancers (PMID: 26160835).', 'references': [{'id': 393, 'pubMedId': 15084261, 'title': 'Cyclin C/cdk3 promotes Rb-dependent G0 exit.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15084261'}, {'id': 4270, 'pubMedId': 26160835, 'title': 'RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26160835'}]}]",RB1,5925,13q14.2,"['OSRC', 'p105-Rb', 'pp110', 'PPP1R130', 'pRb', 'RB']","['RB1', 'OSRC', 'p105-Rb', 'pp110', 'PPP1R130', 'pRb', 'RB']",07/24/2017
0,10,05/25/2013,5979,"[{'description': 'RET, proto-oncogene tyrosine-protein kinase receptor Ret, activates the MAPK pathway for cell proliferation and the PI3K/AKT pathway for cell survival. RET activating mutations and rearrangements are common in medullary thyroid cancer (PMID: 20930041, PMID: 24561444).', 'references': [{'id': 279, 'pubMedId': 20930041, 'title': 'Targeting RET receptor tyrosine kinase activation in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20930041'}, {'id': 3686, 'pubMedId': 24561444, 'title': 'RET revisited: expanding the oncogenic portfolio.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24561444'}]}]",RET,5979,10q11.21,"['CDHF12', 'CDHR16', 'HSCR1', 'MEN2A', 'MEN2B', 'MTC1', 'PTC', 'RET-ELE1']","['RET', 'CDHF12', 'CDHR16', 'HSCR1', 'MEN2A', 'MEN2B', 'MTC1', 'PTC', 'RET-ELE1']",10/01/2017
0,6,05/19/2013,6098,"[{'description': 'ROS1, proto-oncogene tyrosine-protein kinase ROS, activates many signaling pathways, including PI3K/mTOR, and commonly forms oncogenic fusion proteins in a variety of cancers (PMID: 23719267).', 'references': [{'id': 280, 'pubMedId': 23719267, 'title': 'Molecular pathways: ROS1 fusion proteins in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23719267'}]}]",ROS1,6098,6q22.1,"['c-ros-1', 'MCF3', 'ROS']","['ROS1', 'c-ros-1', 'MCF3', 'ROS']",07/24/2017
0,21,05/25/2013,861,"[{'description': 'RUNX1, runt-related transcription factor 1, is a transcription factor that binds to core binding factor beta (CBFB) and plays a role in hematopoiesis (PMID: 22150309, PMID: 23180629). RUNX1 mutations and translocations have been implicated in several hematologic cancers (PMID: 22150309).', 'references': [{'id': 5279, 'pubMedId': 23180629, 'title': 'RUNX family: Regulation and diversification of roles through interacting proteins.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23180629'}, {'id': 281, 'pubMedId': 22150309, 'title': 'RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22150309'}]}]",RUNX1,861,21q22.12,"['AML1', 'AML1-EVI-1', 'AMLCR1', 'CBF2alpha', 'CBFA2', 'EVI-1', 'PEBP2aB', 'PEBP2alpha']","['RUNX1', 'AML1', 'AML1-EVI-1', 'AMLCR1', 'CBF2alpha', 'CBFA2', 'EVI-1', 'PEBP2aB', 'PEBP2alpha']",07/24/2017
0,18,05/22/2013,26040,"[{'description': 'SETBP1, SET binding protein 1, binds to the SET nuclear oncoprotein to regulate targets including the tumor suppressor protein phosphatase type 2a (PP2A). Overexpression and gain of function mutations in Setbp1 have been linked to a variety of myeloproliferative diseases and worse clinical outcomes (PMID: 23892662, PMID: 11231286).', 'references': [{'id': 1598, 'pubMedId': 11231286, 'title': 'Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11231286'}, {'id': 1597, 'pubMedId': 23892662, 'title': 'A new player SETs in myeloid malignancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23892662'}]}]",SETBP1,26040,18q12.3,"['MRD29', 'SEB']","['SETBP1', 'MRD29', 'SEB']",07/24/2017
0,2,05/05/2013,23451,"[{'description': 'SF3B1, splicing factor 3b, subunit 1, is a core member of the U2 small nuclear ribonucleoprotein complex of the spliceosome (PMID: 25510282, PMID: 26842708). Mutations in SF3B1 are frequent in myelodysplastic syndrome and have been identified in several additional hematological and solid tumor types (PMID: 24709888, PMID: 25510282, PMID: 26842708).', 'references': [{'id': 5324, 'pubMedId': 25510282, 'title': 'Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25510282'}, {'id': 5325, 'pubMedId': 26842708, 'title': 'Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842708'}, {'id': 3342, 'pubMedId': 24709888, 'title': 'Rare SF3B1 R625 mutations in cutaneous melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24709888'}]}]",SF3B1,23451,2q33.1,"['Hsh155', 'MDS', 'PRP10', 'PRPF10', 'SAP155', 'SF3b155']","['SF3B1', 'Hsh155', 'MDS', 'PRP10', 'PRPF10', 'SAP155', 'SF3b155']",07/24/2017
0,18,05/25/2013,4089,"[{'description': 'SMAD4, mothers against decapentaplegic homolog 4, translocates to the nucleus upon TGF-beta signaling to form a protein complex that regulates gene transcription and cell growth (PMID: 28452926). Smad4 loss of function or inactivation has been commonly identified in pancreatic cancer and may be a marker for poor prognosis (PMID: 28067794).', 'references': [{'id': 282, 'pubMedId': 20087440, 'title': 'Smad4-mediated TGF-beta signaling in tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20087440'}]}]",SMAD4,4089,18q21.2,"['DPC4', 'JIP', 'MADH4', 'MYHRS']","['SMAD4', 'DPC4', 'JIP', 'MADH4', 'MYHRS']",07/24/2017
0,22,05/29/2013,6598,"[{'description': 'SMARCB1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, is a member of the SWI/SNF chromatin remodeling complex and regulates transcription of several genes involved in cell proliferation (PMID: 23095836). Smarcb1 inactivation is characteristic of atypical teratoid/rhabdoid tumors (PMID: 23095836).', 'references': [{'id': 283, 'pubMedId': 23095836, 'title': 'Molecular markers in pediatric neuro-oncology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23095836'}]}]",SMARCB1,6598,22q11,"['BAF47', 'CSS3', 'hSNFS', 'INI1', 'MRD15', 'PPP1R144', 'RDT', 'RTPS1', 'Sfh1p', 'SNF5', 'SNF5L1', 'Snr1', 'SWNTS1']","['SMARCB1', 'BAF47', 'CSS3', 'hSNFS', 'INI1', 'MRD15', 'PPP1R144', 'RDT', 'RTPS1', 'Sfh1p', 'SNF5', 'SNF5L1', 'Snr1', 'SWNTS1']",07/24/2017
0,10,05/26/2013,9126,"[{'description': 'SMC3, structural maintenance of chromosomes 3, is a component of the cohesin complex, which functions in cohesion of sister chromatids during mitosis (PMID: 24856830, PMID: 23776448). SMC3 mutations have been identified in myeloid cancers as well as several additional tumor types (PMID: 24335498, PMID: 24856830, PMID: 23955599).', 'references': [{'id': 5341, 'pubMedId': 24335498, 'title': 'Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24335498'}, {'id': 5339, 'pubMedId': 24856830, 'title': 'Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24856830'}, {'id': 5342, 'pubMedId': 23955599, 'title': 'Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23955599'}, {'id': 5340, 'pubMedId': 23776448, 'title': 'Imbalance of SMC1 and SMC3 cohesins causes specific and distinct effects.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23776448'}]}]",SMC3,9126,10q25.2,"['BAM', 'BMH', 'CDLS3', 'CSPG6', 'HCAP', 'SMC3L1']","['SMC3', 'BAM', 'BMH', 'CDLS3', 'CSPG6', 'HCAP', 'SMC3L1']",07/24/2017
0,7,05/25/2013,6608,"[{'description': 'SMO, smoothened, frizzled class receptor, is a G-protein coupled receptor and member of the Hedgehog signaling pathway, which is involved in cell fate, proliferation, and survival (PMID: 16881963). SMO gain-of-function mutations are associated with basal cell carcinoma (PMID: 25085664).', 'references': [{'id': 4278, 'pubMedId': 25085664, 'title': 'Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25085664'}, {'id': 274, 'pubMedId': 16881963, 'title': 'Hedgehog signalling in skin development and cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16881963'}]}]",SMO,6608,7q32.1,"['CRJS', 'FZD11', 'Gx', 'SMOH']","['SMO', 'CRJS', 'FZD11', 'Gx', 'SMOH']",07/24/2017
0,20,05/25/2013,6714,"[{'description': 'SRC, proto-oncogene tyrosine-protein kinase Src, is a member of mutliple signaling pathways and activation and/or overexpression has been observed in many cancers (PMID: 24788409).', 'references': [{'id': 284, 'pubMedId': 24788409, 'title': 'c-Src drives intestinal regeneration and transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24788409'}]}]",SRC,6714,20q11.23,"['ASV', 'c-SRC', 'p60-Src', 'SRC1', 'THC6']","['SRC', 'ASV', 'c-SRC', 'p60-Src', 'SRC1', 'THC6']",07/24/2017
0,17,05/25/2013,6427,"[{'description': 'SRSF2, serine/arginine-rich splicing factor 2, functions in exon recognition as part of the spiceosome protein complex during pre-mRNA splicing (PMID: 25510282, PMID: 27151974). Mutations in SRSF2 have been identified in numerous hematological malignancies (PMID: 24523246, PMID: 25510282). ', 'references': [{'id': 1657, 'pubMedId': 23335386, 'title': 'Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23335386'}, {'id': 5324, 'pubMedId': 25510282, 'title': 'Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25510282'}, {'id': 5453, 'pubMedId': 27151974, 'title': 'Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27151974'}, {'id': 1658, 'pubMedId': 24523246, 'title': 'Splicing factor mutations and cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24523246'}]}]",SRSF2,6427,17q25.1,"['PR264', 'SC-35', 'SC35', 'SFRS2', 'SFRS2A', 'SRp30b']","['SRSF2', 'PR264', 'SC-35', 'SC35', 'SFRS2', 'SFRS2A', 'SRp30b']",07/24/2017
0,X,05/18/2013,10735,"[{'description': ""STAG2, stromal antigen 2, functions as part of the cohesin complex to regulate spindle formation and sister chromatid association in cellular mitosis (PMID: 12034751). Somatic mutations of STAG2 have been reported in glioblastoma, Ewing's sarcoma, and melanoma, and loss of Stag2 expression has been detected in a variety of other tumor types, including bladder (PMID: 22668012, PMID: 28627627)."", 'references': [{'id': 9637, 'pubMedId': 28627627, 'title': 'Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28627627'}, {'id': 1659, 'pubMedId': 22668012, 'title': 'Mutational and expressional analyses of STAG2 gene in solid cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22668012'}, {'id': 1660, 'pubMedId': 12034751, 'title': 'STAG2 and Rad21 mammalian mitotic cohesins are implicated in meiosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12034751'}]}]",STAG2,10735,Xq25,"['bA517O1.1', 'SA-2', 'SA2', 'SCC3B']","['STAG2', 'bA517O1.1', 'SA-2', 'SA2', 'SCC3B']",07/31/2017
0,19,05/25/2013,6794,"[{'description': 'STK11, serine/threonine kinase 11, is involved in cell metabolism, growth, polarity, and tumor suppression through the regulation of AMPK family members (PMID: 26398719). Germline STK11 mutations cause Peutz–Jeghers syndrome, somatic STK11 mutations are identified in melanoma, lung, pancreatic, cervical, and endometrial cancers (PMID: 26877140).', 'references': [{'id': 9856, 'pubMedId': 26877140, 'title': 'Energy sensing and cancer: LKB1 function and lessons learnt from Peutz-Jeghers syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26877140'}, {'id': 9855, 'pubMedId': 26398719, 'title': 'Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26398719'}]}]",STK11,6794,19p13.3,"['hLKB1', 'LKB1', 'PJS']","['STK11', 'hLKB1', 'LKB1', 'PJS']",09/01/2017
0,4,05/05/2013,54790,"[{'description': 'TET2, tet methylcytosine dioxygenase 2, plays a role in DNA methylation and is involved in hematopoesis (PMID: 26099018, PMID: 25510268). TET2 has been identified as a tumor suppressor in hematological malignancies, and mutations in TET2 are common in hematological cancers including myelodysplastic syndrome and chronic myelomoncytic leukemia (PMID: 26099018, PMID: 22240200).', 'references': [{'id': 5476, 'pubMedId': 25510268, 'title': 'TET proteins and 5-methylcytosine oxidation in hematological cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25510268'}, {'id': 897, 'pubMedId': 22240200, 'title': 'TET2, a tumor suppressor in hematological disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22240200'}, {'id': 5475, 'pubMedId': 26099018, 'title': 'The TET2 interactors and their links to hematological malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26099018'}]}]",TET2,54790,4q24,"['KIAA1546', 'MDS']","['TET2', 'KIAA1546', 'MDS']",07/24/2017
0,17,05/26/2013,7157,"[{'description': 'TP53, tumor protein p53, is a tumor suppressor involved in cell cycle arrest and apoptosis, and is the most frequently mutated gene in cancer (PMID: 10065147, PMID: 22713868). Mutations in TP53 have been implicated in chemoresistance (PMID: 9927204, PMID: 24065105, PMID: 27066457).', 'references': [{'id': 12, 'pubMedId': 10065147, 'title': 'Introduction: p53--the first twenty years.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10065147'}, {'id': 5884, 'pubMedId': 9927204, 'title': 'Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9927204'}, {'id': 5885, 'pubMedId': 24065105, 'title': 'The consequence of oncomorphic TP53 mutations in ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065105'}, {'id': 2397, 'pubMedId': 22713868, 'title': 'Mutant p53: one name, many proteins.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22713868'}, {'id': 5886, 'pubMedId': 27066457, 'title': 'Oncogenic Intra-p53 Family Member Interactions in Human Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27066457'}]}]",TP53,7157,17p13.1,"['BCC7', 'LFS1', 'P53', 'TRP53']","['TP53', 'BCC7', 'LFS1', 'P53', 'TRP53']",08/29/2017
0,21,05/18/2013,7307,"[{'description': ""U2AF1, U2 small nuclear RNA auxiliary factor 1, is the 35-kDa subunit of the U2AF heterodimer, which functions in 3' splice site recognition, and is frequently mutated in hematological cancers and in lung adenocarcinoma (PMID: 23645565, PMID: 22678168, PMID: 24498085). "", 'references': [{'id': 1725, 'pubMedId': 22678168, 'title': 'Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22678168'}, {'id': 1726, 'pubMedId': 22980975, 'title': 'Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22980975'}, {'id': 1724, 'pubMedId': 23645565, 'title': 'The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23645565'}, {'id': 1727, 'pubMedId': 24498085, 'title': 'A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24498085'}]}]",U2AF1,7307,21q22.3,"['FP793', 'RN', 'RNU2AF1', 'U2AF35', 'U2AFBP']","['U2AF1', 'FP793', 'RN', 'RNU2AF1', 'U2AF35', 'U2AFBP']",07/24/2017
0,3,05/26/2013,7428,"[{'description': 'VHL, von Hippel-Lindau tumor suppressor, is part of an E3 ubiquitin protein ligase complex, which promotes degradation of HIF-alpha (PMID: 24583008). VHL contributes to von Hippel-Lindau disease and sporadic tumors, including clear cell renal carcinoma (PMID: 24583008).', 'references': [{'id': 290, 'pubMedId': 24583008, 'title': 'The multifaceted von Hippel-Lindau tumour suppressor protein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24583008'}]}]",VHL,7428,3p25.3,"['HRCA1', 'pVHL', 'RCA1', 'VHL1']","['VHL', 'HRCA1', 'pVHL', 'RCA1', 'VHL1']",09/01/2017
0,X,05/14/2013,8233,"[{'description': ""ZRSR2, zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2, is a component of the splicesome that functions in 3' splice site recognition (PMID: 21041408, PMID: 25586593). ZRSR2 mutations are associated with myelodysplastic syndromes (PMID: 21909114, PMID: 26769228)."", 'references': [{'id': 5327, 'pubMedId': 26769228, 'title': 'Myelodysplastic syndromes: Contemporary review and how we treat.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769228'}, {'id': 5586, 'pubMedId': 21909114, 'title': 'Frequent pathway mutations of splicing machinery in myelodysplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21909114'}, {'id': 5584, 'pubMedId': 21041408, 'title': ""The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21041408'}, {'id': 5585, 'pubMedId': 25586593, 'title': 'Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25586593'}]}]",ZRSR2,8233,Xp22.2,"['U2AF1-RS2', 'U2AF1L2', 'U2AF1RS2', 'URP', 'ZC3H22']","['ZRSR2', 'U2AF1-RS2', 'U2AF1L2', 'U2AF1RS2', 'URP', 'ZC3H22']",07/24/2017
